Omicron News and Research

RSS
Study tracks the rapid shift from Omicron BA.1 to BA.2 sub-variant dominance in Sweden

Study tracks the rapid shift from Omicron BA.1 to BA.2 sub-variant dominance in Sweden

29 Mar 2022
Immune response dynamics following COVID-19 heterologous and homologous vaccinations

Immune response dynamics following COVID-19 heterologous and homologous vaccinations

29 Mar 2022
Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

29 Mar 2022
New compound delivered in a nasal spray effectively treats delta variant infection in mice

New compound delivered in a nasal spray effectively treats delta variant infection in mice

29 Mar 2022
Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly

28 Mar 2022
Natural SARS-CoV-2 antibodies persist for six months in children

Natural SARS-CoV-2 antibodies persist for six months in children

28 Mar 2022
Hybrid immunity and booster vaccination provides best protection against SARS-CoV-2 BA.1 and BA.2

Hybrid immunity and booster vaccination provides best protection against SARS-CoV-2 BA.1 and BA.2

28 Mar 2022
COVID-19 vaccination continues to protect adults against severe illness and death

COVID-19 vaccination continues to protect adults against severe illness and death

28 Mar 2022
Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

28 Mar 2022
Dynamics of SARS-CoV-2 viral load in vaccinated and recovered individuals

Dynamics of SARS-CoV-2 viral load in vaccinated and recovered individuals

28 Mar 2022
Study estimates protection against reinfection following primary SARS-CoV-2 infection

Study estimates protection against reinfection following primary SARS-CoV-2 infection

28 Mar 2022
Benefits of heterotypic vaccination against variants of SARS-CoV-2

Benefits of heterotypic vaccination against variants of SARS-CoV-2

28 Mar 2022
Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

28 Mar 2022
Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

28 Mar 2022
Severe outcomes in hospitalized children during the Omicron BA.2-dominated fifth wave in Hong Kong

Severe outcomes in hospitalized children during the Omicron BA.2-dominated fifth wave in Hong Kong

28 Mar 2022
Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

27 Mar 2022
Clinical determinants of post-COVID-19 thromboembolism

Clinical determinants of post-COVID-19 thromboembolism

27 Mar 2022
U.S. traveler-based genomic surveillance provided early SARS-CoV-2 variant detection

U.S. traveler-based genomic surveillance provided early SARS-CoV-2 variant detection

27 Mar 2022
Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

25 Mar 2022
A new strategy for identifying potent miniature antibodies against emerging SARS-CoV-2 variants

A new strategy for identifying potent miniature antibodies against emerging SARS-CoV-2 variants

25 Mar 2022

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback